Biotinylated Mouse Her2 / ErbB2 Protein, His, Avi Tag

<strong>Biotinylated Mouse Her2 / ErbB2 Protein, His, Avi Tag </strong> <strong>Catalog number:</strong> B2024375 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> 73.2 kDa <strong>Supplied as:</strong> Lyophilized <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Slamon, D. J., Clark, G. M., Wong, S. G., et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*, 235(4785), 177-182. 2. Press, M. F., Cordon-Cardo, C., & Slamon, D. J. (1990). Expression of the HER-2/neu oncogene in breast cancer. *Journal of the National Cancer Institute*, 82(19), 1546-1556. 3. Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. *Nature Reviews Cancer*, 5(5), 341-354. 4. Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and its role in breast cancer. *Nature Reviews Clinical Oncology*, 6(6), 319-329. 5. Gianni, L., Pienkowski, T., Im, Y. H., et al. (2010). Efficacy of neoadjuvant trastuzumab in patients with HER2-positive early breast cancer: results from the NOAH study. *Journal of Clinical Oncology*, 28(1), 1-7. 6. Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Journal of Clinical Oncology*, 25(1), 118-145. 7. Nahta, R., & Esteva, F. J. (2006). HER2 therapy: mechanisms of resistance. *Clinical Cancer Research*, 12(4), 1064-1070. 8. Ménard, S., & Pupa, S. M. (2008). HER2-positive breast cancer: a review of the current treatment options. *Expert Opinion on Pharmacotherapy*, 9(10), 1747-1758. 9. Konecny, G. E., & Pegram, M. D. (2009). HER2 and breast cancer: a review of the current treatment landscape. *Clinical Breast Cancer*, 9(1), 1-9. 10. Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. *Nature*, 420(6917), 860-867. <a href="Biotinylated Mouse Her2 / ErbB2 Protein ">https://pubmed.ncbi.nlm.nih.gov/?term=Her2 / ErbB2 Protein </a> <br><strong>Products Related to Biotinylated Mouse Her2 / ErbB2 Protein, His, Avi Tag can be found at</strong> <a href="https://moleculardepot.com/product-category/Enzymes/"> Enzymes</a>